Piqray – basic questions at the start: whom to test? whom to treat? how to treat? Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 29th, 2021
A Satellite Symposium of Novartis Pharma was held on January 29th, 2021, within the framework of the RUSSCO Big Conference Breast Cancer. It was dedicated to the diagnostics and treatment of patients with hormone-dependent HER2-negative advanced breast cancer (HR+ HER2- aBC) with a PIK3CA mutation u...
Saved in:
Main Author: | Editorial Board |
---|---|
Format: | article |
Language: | RU |
Published: |
IP Habib O.N.
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/a6d2aec1f0f646d38f5a81aae27f6f67 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
by: Editorial Board
Published: (2021) -
The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
by: Natalya V. Mazurina, et al.
Published: (2021) -
The frequency and spectrum of PIK3CA mutations in patients with estrogen receptor-positive HER2-negative advanced breast cancer residing in various regions of Russia
by: Tatiana N. Sokolova, et al.
Published: (2021) -
Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data
by: Armaghani AJ, et al.
Published: (2020) -
The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review
by: Irina V. Poddubnaya, et al.
Published: (2021)